The leukemia strikes back: a review of pathogenesis and treatment of secondary AML
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03606-0
Abstract: Secondary AML is associated with a disproportionately poor prognosis, consistently shown to exhibit inferior response rates, event-free survival, and overall survival in comparison with de novo AML. Secondary AML may arise from the evolution of… read more here.
Keywords: strikes back; aml; back review; treatment ... See more keywords
Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117415
Abstract: Background: To help optimize decision-making for acute myeloid leukemia (AML) treatment in the clinic, risk models comprising different variables were developed. A Treatment-Related Mortality (TRM) model was developed to predict 28-day mortality. The TRM model… read more here.
Keywords: performance status; mortality; model; secondary aml ... See more keywords
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006158
Abstract: Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise… read more here.
Keywords: myelodysplastic syndromes; secondary aml; tp53 mutant; tp53 mutations ... See more keywords